Table 2.
Differences in clinical and demographic characteristics of NAFLD and MAFLD criteria in patients with BMI ≥ 25 kg/m2 (n = 2351).
| Characteristic | NAFLD (n = 1495) % (n)/μ ± SD |
MAFLD (n = 1536) % (n)/μ ± SD |
p | Effect Size (Cohen’s d/w) | |
|---|---|---|---|---|---|
| Male | 71.6 (1071) | 71.4 (1097) | 0.90 | 0.28 | Small |
| Age (years) | 50.8 ± 13.1 | 51.1 ± 13.1 | 0.52 | −0.01 | Null |
| DM | 11.4 (170) | 13.7 (211) | 0.05 | 0.87 | Large |
| HBP | 20.7 (310) | 21.5 (330) | 0.62 | 0.78 | Medium |
| BMI (kg/m2) | 29.5 ± 3.5 | 29.5 ± 3.5 | 1.00 | −0.70 | Null |
| Glucose (g/dL) | 100.2 ± 25.8 | 100.7 ± 26.3 | 0.59 | −0.31 | Null |
| HbA1c (%) | 5.6 ± 0.9 | 5.6 ± 0.9 | 1.00 | −0.28 | Null |
| SBP (mmHg) | 117.3 ± 15.8 | 117.4 ± 15.8 | 0.86 | −0.27 | Null |
| DBP (mmHg) | 76.7 ± 9.3 | 76.6 ± 9.4 | 0.76 | −0.37 | Null |
| Triglycerides (mg/dL) | 165.8 ± 99 | 165.2 ± 98.4 | 0.86 | −0.37 | Null |
| HDL (mg/dL) | 44.3 ± 18 | 44.3 ± 17.9 | 1.00 | 0.22 | Small |
| CRP (mg/L) | 3.2 ± 5.9 | 3.3 ± 6.8 | 0.66 | −0.10 | Null |
| WC (cm) | 100.7 ± 9.7 | 100.6 ± 9.7 | 0.77 | −0.74 | Null |
| CAP (dB/m) | 311.7 ± 35.7 | 309.5 ± 38 | 0.10 | −2.44 | Null |
| S1 | 23.7 (355) | 23.1 (355) | 0.69 | 0.76 | Medium |
| S2 | 15.5 (232) | 15.1 (232) | 0.76 | 0.84 | Large |
| S3 | 59.3 (886) | 57.7 (886) | 0.39 | 0.41 | Small |
| kPa | 4.6 ± 1.9 | 4.6 ± 1.9 | 1.00 | −0.23 | Null |
| Significant fibrosis 7–10 kPa |
1.6 (24) | 1.6 (25) | 1.00 | 0.98 | Large |
| Advanced fibrosis >10 kPa |
1.3 (20) | 1.4 (22) | 0.87 | 0.98 | Large |
DM: diabetes mellitus; HBP: high blood pressure; BMI: body mass index; HbA1C: glycosylated hemoglobin; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high density lipoprotein; CRP: C reactive protein; WC: waist circumference; CAP: controlled attenuation parameter.